Levodopa News and Research

RSS

CRISPR/sgRNA-SAM therapy: a potential breakthrough for Parkinson's disease?

Researchers utilize the CRISPR-Cas9 system to induce the synthesis of dopamine (DA) in the brains of a rat model for Parkinson’s disease.

11 Aug 2023

Digital technologies for effective geriatric care: successes, challenges and future perspectives

Researchers discussed the current achievements, challenges, and potential opportunities in using digital technologies.

21 Jul 2023

Multiple discoveries open new paths for early prediction of Parkinson's disease trajectories

Hand tremors and slowed movements are two of the most widely recognized hallmarks of Parkinson's disease, and for many sufferers the first indication that something is amiss.

6 Jul 2023

What role does dysbiosis play in Parkinson's disease?

The current study, published in the journal Revue Neurologique, is based on the hypothesis that dysbiosis, or unhealthy variations in the gut and oral microbiota, is a key component of PD pathogenesis.

19 Mar 2023

Exploring the neuroprotective potential of cell-penetrating peptides, extracellular vesicles, and micro ribonucleic acids

In a recent review published in Biomedicines, researchers explored extracellular vesicles (EVs), cell-penetrating peptides (CPPs), and micro ribonucleic acids (miRNAs) as therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

1 Mar 2023

Researchers report on a genome-wide reconstruction of human microbes to develop personalized therapies

Researchers reported on AGORA2, an expansion of their previously published resource, AGORA, of genomewide metabolic reconstructions of human intestinal microbes.

26 Jan 2023

The currently available evidence on viral-induced parkinsonism

A new review attempts to summarize all known about the relationship between viral illness and parkinsonian disorders to facilitate further research.

31 Aug 2022

Research suggests a new pathway for developing Parkinson's disease

There is currently no cure for Parkinson's disease (PD), and one of the main difficulties for developing treatments is that we don't know exactly how or why the disease occurs.

4 Jul 2022

Study uncovers a promising drug candidate to minimize dyskinesia in Parkinson's patients

A new study from Texas Biomedical Research Institute (Texas Biomed) and collaborators has identified a promising drug candidate to minimize uncontrolled, erratic muscle movements, called dyskinesia, associated with Parkinson's disease.

1 Dec 2021

Northwestern scientists receive awards totaling nearly $18 million for Parkinson's disease research

Northwestern University scientists have received two awards totaling nearly $18 million for Parkinson's disease research from The ASAP Collaborative Research Network, a program of the Aligning Science Across Parkinson's (ASAP) initiative being implemented through The Michael J. Fox Foundation.

27 Oct 2021

Using deep brain stimulation to treat Parkinson’s Disease

News-Medical spoke to Dr. Aryn Gittis about her latest research into Parkinson's disease and how deep brain stimulation could be used to help treat it.

27 Oct 2021

Increased signaling by sonic hedgehog protein can inhibit LID in Parkinson's patients

Levodopa, or L-dopa, is considered the most effective treatment for Parkinson's disease today. After a few years of treatment, however, almost all patients develop a debilitating side-effect called L-dopa induced dyskinesia, or LID, which causes involuntary movements in the limbs, face, and torso. Deep brain stimulation can alleviate LID, but the procedure is highly invasive and not all patients are eligible.

23 Sep 2021

European study sheds light on the burden of Parkinson’s disease in patients and their carers

Results of a new European study published in the Journal of Parkinson's Disease may help improve clinical practice by shedding light on the lives of people with PD and their carers, re-emphasizing the many challenges they face in everyday life.

31 Aug 2021

Gene therapy shows promise in children with devastating genetic disorder

Children with a devastating genetic disorder characterized by severe motor disability and developmental delay have experienced sometimes dramatic improvements in a gene therapy trial launched at UCSF Benioff Children's Hospitals.

12 Jul 2021

Nanoscale coordination polymers show promise for efficient dopamine delivery in Parkinson's treatment

Parkinson's disease (PD) is a common neurodegenerative disorder caused by the death of dopaminergic neurons in a part of the brain (known as substantia nigra pars compacta), which leads to a deficit of dopamine (DA), one of the main neurotransmitters active in the central nervous system.

1 Jun 2021

New gel could be used as nasal spray for treating Parkinson's patients

Scientists at the University of York have made significant progress in the development of a nasal spray treatment for patients with Parkinson's disease.

25 May 2021

Step length synergy while crossing obstacles found to be lower in Parkinson’s patients

A multidisciplinary research group affiliated with the Department of Physical Education's Human Movement Laboratory at São Paulo State University in Bauru, Brazil, measured step length synergy while crossing obstacles in patients with Parkinson's disease and concluded that it was 53% lower than in healthy subjects of the same age and weight. Step length is one of the main variables affected by the disease.

7 Apr 2021